FILTER
FILTERED INTERVIEW RESULTS
Daniel Mitchell
PRESIDENT, ACOPLÁSTICOS
Acoplásticos explains how Colombia’s chemical industry has coped with the COVID-19 pandemic.
Rodrigo Gutierrez
CEO, GTM HOLDINGS
GTM Holdings explains its outlook for the Latin American industrial and specialty chemicals market for the next year.
Martin Cini
DIRECTOR, COPSA COMBUSTIBLES, QUÍMICOS Y ESPECIALIDADES
Copsa is an Argentinian petrochemical company currently expanding its products and services.
Martin Sack
REGIONAL HEAD AMERICAS, LESCHACO
Leschaco is a freight forwarder expanding its’ services and network across the Americas.
Bob Masterson
CEO, CHEMISTRY INDUSTRY ASSOCIATION OF CANADA (CIAC)
CIAC explains the current evolution of Canada’s industrial chemicals segment.
Jan Krueder & Matthias Vorbeck
CEO, QUÍMICA ANASTACIO & GENERAL MANAGER, ANASTACIO OVERSEAS
Chemical distributer Anastacio sees opportunities for growth across Latin America.
Marcos De Marchi
CEO, ELEKEIROZ
Elekeiroz speaks to GBR about the market conditions for petrochemicals in Brazil and how reforms can help the industry.
Federico Veller
EXECUTIVE MANAGER CHEMICALS, YPF
YPF explains how the company has evolved to benefit from the development of Vaca Muerta.
Edison Terra
VICE PRESIDENT OF OLEFINS AND POLYOLEFINS UNIT FOR SOUTH AMERICA, BRASKEM
Braskem is the largest petrochemical company in the Americas, the largest producer of polypropylene in the US, and a global leader in biopolymers production.
Martin Toscano
MANAGING DIRECTOR, EVONIK INDUSTRIES (MEXICO)
Evonik enjoys rapid growth in Mexico across all sectors, both in market share for existing products and as a result of acquisitions and diversification.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
